TiKa Diagnostics Ltd
We serve you in mycobacterial diagnostics.
TiKa Diagnostics Ltd is a spin out company from St George’s, University of London. It is based on the discovery of Dr Tim Bull and Kai Hilpert.

In a nutshell for diagnostics in humans: TiKa Diagnostics Ltd has invented a new test able to confirm the diagnosis of Tuberculosis (TB) in adults and children significantly faster, more sensitive and with less contaminations than has been previously possible. We have shown that using our new culture system, we can grow the bacterium that causes TB much faster and from a wider range of types of samples. We have shown that our products can be easily incorporated and will enhance existing routine clinical laboratory methods. This innovation will help doctors make faster, more informed decisions on tuberculosis treatments, leading to improving the efficiency of care, helping stop the spread of disease and better rationalisation of the cost for hospital stays. 

In a nutshell for diagnostics in animals: TiKa Diagnostics Ltd has invented a new test able to confirm the diagnosis of Mycobacterium bovis and  Mycobacterium avium subspecies paratuberculosis (MAP) in cows and budgers significantly faster, more sensitive and with less contaminations than has been previously posssible. We have shown that using our new culture system, we can grow these bacteria much faster and from a wider range of types of samples. We have shown that our products can be easily incorporated and will enhance existing routine clinical laboratory methods. This innovation will help veterinaries  make faster, more informed decisions on tuberculosis treatments, leading to improving the efficiency of herd control, helping stop the spread of disease and better rationalisation of eradication TB in humans. 

Meet The Senior Managment
  1. Director - CSO/CEO
    Director - CSO/CEO
    Dr Tim Bull
    Dr Tim Bull is a Reader in Infectious Diseases at St George’s, University of London. He is an internationally recognised expert in mycobacterial diseases and has over 20 years experience in working with culturing mycobacteria.
  2. Director - CPO/CEO
    Director - CPO/CEO
    Dr Kai Hilpert
    Dr. Kai Hilpert is a Reader in Infection and Immunology at St George’s, University of London. He has 15 years experience in synthesis and screening of natural products in various projects. He also works successful on novel antimicrobial against multi-drug resistant bacteria and fungi.
  3. Director
    Director
    Nicola Arnold
    Nicola Arnold is a chartered accountant and Director of Finance at St George’s, University of London. She was previously Deputy Director of Finance at UCL and has also worked at Ernst and Young and the BBC.
We Strive For Excellent Service.
Background information:
The World Health Organisation estimates that over 1/3 of the world’s population are latently infected with mycobacteria. More than 60 million people are tested for mycobacterial infections each year. Investigations and follow up cost £1.5 billion worldwide with treatment of UK cases of multidrug resistant mycobacterial infections costing up to £7,000 per patient. Culture of a pathogen from an appropriate patient sample is still the gold standard for diagnosis but despite over 100 years of development in mycobacteria culture methodology, producing growth is frustratingly slow, inaccurate and particularly in samples with very low numbers of pathogens, can be impossible. This is because as adapted intracellular human pathogens, mycobacteria are able to stop dividing and become dormant on entry into the host. Initiating mycobacterial regrowth from patient samples is not assured and those proportions that do begin growing often require many weeks, sometimes months to generate observable growth. This slow detection time is detrimental to effective national health strategies dealing with mycobacterial diseases and has led to culture methods whilst remaining definitive, of only retrospective diagnostic worth.